Live feed11:45:00·654dPRReleasevia QuantisnowIvonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in ChinaByQuantisnow·Wall Street's wire, on your screen.SMMT· Summit Therapeutics Inc.Health Care
